Moon Thomas M, Tykocki Nathan R, Sheehe Jessica L, Osborne Brent W, Tegge Werner, Brayden Joseph E, Dostmann Wolfgang R
Department of Pharmacology, College of Medicine, The University of Vermont, 89 Beaumont Avenue, Burlington, VT 05405, USA.
Department of Chemical Biology, Helmholtz Centre for Infection Research (HZI), Inhoffenstraße 7, 38124 Braunschweig, Germany.
Chem Biol. 2015 Dec 17;22(12):1653-61. doi: 10.1016/j.chembiol.2015.11.005.
PKG is a multifaceted signaling molecule and potential pharmaceutical target due to its role in smooth muscle function. A helix identified in the structure of the regulatory domain of PKG Iα suggests a novel architecture of the holoenzyme. In this study, a set of synthetic peptides (S-tides), derived from this helix, was found to bind to and activate PKG Iα in a cyclic guanosine monophosphate (cGMP)-independent manner. The most potent S-tide derivative (S1.5) increased the open probability of the potassium channel KCa1.1 to levels equivalent to saturating cGMP. Introduction of S1.5 to smooth muscle cells in isolated, endothelium-denuded cerebral arteries through a modified reversible permeabilization procedure inhibited myogenic constriction. In contrast, in endothelium-intact vessels S1.5 had no effect on myogenic tone. This suggests that PKG Iα activation by S1.5 in vascular smooth muscle would be sufficient to inhibit augmented arterial contractility that frequently occurs following endothelial damage associated with cardiovascular disease.
由于PKG在平滑肌功能中发挥作用,它是一种多面性的信号分子和潜在的药物靶点。在PKG Iα调节结构域的结构中鉴定出的一个螺旋表明了全酶的一种新结构。在本研究中,发现一组源自该螺旋的合成肽(S肽)以一种不依赖环磷酸鸟苷(cGMP)的方式结合并激活PKG Iα。最有效的S肽衍生物(S1.5)将钾通道KCa1.1的开放概率提高到与饱和cGMP相当的水平。通过改良的可逆通透化程序将S1.5引入分离的、去内皮的脑动脉平滑肌细胞中,可抑制肌源性收缩。相反,在完整内皮的血管中,S1.5对肌源性张力没有影响。这表明S1.5在血管平滑肌中激活PKG Iα足以抑制与心血管疾病相关的内皮损伤后经常出现的动脉收缩增强。